Stock price plunges 70%! Bio-Rad Laboratories (BIO.US) trapped in a low point, aggressive investor Elliott enters the game.

According to reports, the activist investor Elliott Investment Management has purchased a large amount of shares in Bio-Rad Laboratories (BIO.US) with plans to boost the stock performance of this life science instrument supplier. The scale of Elliott's stake in Bio-Rad Laboratories is not yet clear. Bio-Rad currently has a market value of about $6.7 billion, and its stock price has dropped over 70% since reaching a high at the end of 2021. Sources reveal that Elliott is a significant investor in the German biopharmaceutical equipment supplier Sartorius. It is reported that Bio-Rad also invested in Sartorius, with their stake in Sartorius valued at about $5 billion. Reports indicate that Elliott believes Sartorius is a high-quality company with strong growth potential. After announcing a net loss of $527 million in the first quarter of this year, Bio-Rad lowered its revenue growth guidance for 2026. The company attributed its poor performance to the fair value changes in its investment in Sartorius. Bio-Rad's stock price has dropped by approximately 18% in 2026, plunging 70% from its historical high during the pandemic period in 2021. The company had benefited greatly from strong demand for its COVID-19 testing products, but as the pandemic gradually subsides, this windfall quickly diminishes, leaving the company in a dilemma of finding new growth opportunities. Elliott, managing around $80 billion in assets, has been investing in the healthcare industry. The company has recently also invested in Charles River Laboratories International, Inc. (CRL.US).